×
S&P 500   3,808.11 (-0.35%)
DOW   30,952.68 (+0.02%)
QQQ   282.69 (-0.30%)
AAPL   139.20 (+1.28%)
MSFT   259.47 (+1.17%)
META   162.62 (+1.21%)
GOOGL   2,224.50 (-0.70%)
AMZN   108.37 (+0.90%)
TSLA   669.15 (-4.13%)
NVDA   153.66 (-3.85%)
NIO   21.60 (-3.40%)
BABA   115.63 (-0.97%)
AMD   76.82 (-4.90%)
MU   55.56 (-3.98%)
CGC   3.50 (-3.05%)
T   20.86 (+1.21%)
GE   63.86 (-3.07%)
F   11.45 (-3.05%)
DIS   94.93 (-1.03%)
AMC   13.38 (-0.15%)
PFE   50.98 (+0.63%)
PYPL   70.94 (-1.23%)
NFLX   176.15 (-1.92%)
S&P 500   3,808.11 (-0.35%)
DOW   30,952.68 (+0.02%)
QQQ   282.69 (-0.30%)
AAPL   139.20 (+1.28%)
MSFT   259.47 (+1.17%)
META   162.62 (+1.21%)
GOOGL   2,224.50 (-0.70%)
AMZN   108.37 (+0.90%)
TSLA   669.15 (-4.13%)
NVDA   153.66 (-3.85%)
NIO   21.60 (-3.40%)
BABA   115.63 (-0.97%)
AMD   76.82 (-4.90%)
MU   55.56 (-3.98%)
CGC   3.50 (-3.05%)
T   20.86 (+1.21%)
GE   63.86 (-3.07%)
F   11.45 (-3.05%)
DIS   94.93 (-1.03%)
AMC   13.38 (-0.15%)
PFE   50.98 (+0.63%)
PYPL   70.94 (-1.23%)
NFLX   176.15 (-1.92%)
S&P 500   3,808.11 (-0.35%)
DOW   30,952.68 (+0.02%)
QQQ   282.69 (-0.30%)
AAPL   139.20 (+1.28%)
MSFT   259.47 (+1.17%)
META   162.62 (+1.21%)
GOOGL   2,224.50 (-0.70%)
AMZN   108.37 (+0.90%)
TSLA   669.15 (-4.13%)
NVDA   153.66 (-3.85%)
NIO   21.60 (-3.40%)
BABA   115.63 (-0.97%)
AMD   76.82 (-4.90%)
MU   55.56 (-3.98%)
CGC   3.50 (-3.05%)
T   20.86 (+1.21%)
GE   63.86 (-3.07%)
F   11.45 (-3.05%)
DIS   94.93 (-1.03%)
AMC   13.38 (-0.15%)
PFE   50.98 (+0.63%)
PYPL   70.94 (-1.23%)
NFLX   176.15 (-1.92%)
S&P 500   3,808.11 (-0.35%)
DOW   30,952.68 (+0.02%)
QQQ   282.69 (-0.30%)
AAPL   139.20 (+1.28%)
MSFT   259.47 (+1.17%)
META   162.62 (+1.21%)
GOOGL   2,224.50 (-0.70%)
AMZN   108.37 (+0.90%)
TSLA   669.15 (-4.13%)
NVDA   153.66 (-3.85%)
NIO   21.60 (-3.40%)
BABA   115.63 (-0.97%)
AMD   76.82 (-4.90%)
MU   55.56 (-3.98%)
CGC   3.50 (-3.05%)
T   20.86 (+1.21%)
GE   63.86 (-3.07%)
F   11.45 (-3.05%)
DIS   94.93 (-1.03%)
AMC   13.38 (-0.15%)
PFE   50.98 (+0.63%)
PYPL   70.94 (-1.23%)
NFLX   176.15 (-1.92%)

Volatile Times Are When AbbVie Shines the Brightest

Monday, May 16, 2022 | Chris Markoch
Volatile Times Are When AbbVie Shines the Brightest

A rock-solid dividend means investors don’t need much growth to get a generous total return 

In the interest of full disclosure, I did it again. Or what’s more accurate to say is...I didn’t do it again. For yet another quarter, I talked myself out of pulling the trigger on AbbVie (NYSE: ABBV) before its ex-dividend date in April. That means I missed out, again, on getting a piece of a reliable, growing dividend. 

Now some people would say it’s a good thing I didn’t because about two weeks after ABBV stock went ex-dividend, the company reported its first-quarter 2022 earnings. And suffice it to say the market didn’t like it. Or maybe they did, but they felt there was just enough bad in it to justify knocking 6% off the company’s share price.   

And with institutional investors feverishly working to reprice the market, ABBV stock hasn’t fully recovered that loss. But the good news for investors (like me) who are considering investing in ABBV stock, is that a little growth can go a long way. That’s because of the aforementioned dividend which makes it more than worthwhile to hold on to ABBV stock.  

Dealing With Humira Patent Expiration 

A key concern for investors is the impact on revenue as the company is preparing to lose its patent protection on Humira in the United States. As sales in Europe are showing, there will be some effect. However, it’s not happening as sharply as expected. In fact, international sales of Humira came in at $740 million. That means, even with an 18% decline, it still puts the company on track to generate about $3 billion annually.  


On its face that’s good news for what is likely to happen when AbbVie loses its patent protection for Humira in the United States. But there’s a larger takeaway for investors.  

For a company like AbbVie, it’s all about the pipeline. And AbbVie has two in-market drugs that targe the same indications as Humira. Skyrizi and Rinvoq have patent protections (for now) and are delivering an increasing piece of revenue. In the last quarter, those two drugs contributed approximately $1.4 billion to the company’s top line. That puts it on pace to eclipse $5 billion this year.  

Skyrizi showed a 64% year-over-year (YOY) increase and Rinvoq showed a 54% YOY increase. Those growth rates are likely to be unsustainable. However, it’s not hard to see the combined revenue doubling in the next few years.   

Investors Get a Chance to Double Dip 

ABBV stock is up 123% since the onset of the pandemic. That’s on par with many of the top growth stocks. But that’s an outlier. From January 2013 through the end of December 2019, ABBV stock averaged 22% growth. But even that may be an outlier. Some analysts are suggesting that, with tightening monetary policy, investors may recalibrate their expectations for growth.  

That plays to AbbVie’s strength. Because even if the company can “only” generate growth in the high single digits, the company’s rock-solid dividend can easily help give investors a double-digit total return. 

Don’t Make My Mistake 

One reason that I stayed on the sidelines with ABBV stock was that, at around $170 a share, it was hard to see much growth. But now that the stock has pulled back, investors are getting a chance to buy ABBV stock at a more attractive price. The company doesn’t report earnings until the end of July, so there won’t probably won’t be much news until then.  

However, ABBV stock will go ex-dividend in mid-July. If you’re like me, you’ll want to make sure you get on the stock before then. Because at times like this, AbbVie appears to be a good place to park some of your hard-earned capital.  

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
AbbVie (ABBV)
3.026 of 5 stars
$155.97+2.3%3.62%22.38Moderate Buy$159.75
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in AbbVie right now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:


Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastHow to Profit In The Bear Market

Today, Kate is joined by a repeat guest, Rob Isbitts of Sungarden Investment Publishing. Rob specializes in ETF portfolios designed to deliver returns in any kind of market condition, including the current bear. In this conversation, Rob gives specific ideas for handling various allocations in your portfolio, and discusses how to approach inverse ETFs.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.